Bank of New York Mellon’s Iovance Biotherapeutics IOVA Stock Holding History

Bank of New York Mellon’s Portfolio IOVA Stock Details IOVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.83M	Buy	1,162,097 +205,317	+21%	+$780K	﹤0.01%	2457
2026 Q1	$3.36M	Buy	956,780 +1,313	+0.1%	+$4.2K	﹤0.01%	2531
2025 Q4	$2.61M	Buy	955,467 +148,283	+18%	+$343K	﹤0.01%	2693
2025 Q3	$1.75M	Buy	807,184 +26,557	+3%	+$62.7K	﹤0.01%	2876
2025 Q2	$1.34M	Sell	780,627 -137,583	-15%	-$342K	﹤0.01%	2951
2025 Q1	$3.06M	Buy	918,210 +52,376	+6%	+$270K	﹤0.01%	2465
2024 Q4	$6.41M	Buy	865,834 +23,865	+3%	+$221K	﹤0.01%	2160
2024 Q3	$7.91M	Sell	841,969 -192,791	-19%	-$1.83M	﹤0.01%	2061
2024 Q2	$8.3M	Buy	1,034,760 +200,536	+24%	+$2.15M	﹤0.01%	2059
2024 Q1	$12.4M	Sell	834,224 -15,981	-2%	-$186K	﹤0.01%	1854
2023 Q4	$6.91M	Sell	850,205 -3,739	-0.4%	-$19.6K	﹤0.01%	2207
2023 Q3	$3.89M	Buy	853,944 +56,160	+7%	+$367K	﹤0.01%	2444
2023 Q2	$5.62M	Buy	797,784 +209,779	+36%	+$1.5M	﹤0.01%	2255
2023 Q1	$3.59M	Sell	588,005 -11,848	-2%	-$81.7K	﹤0.01%	2477
2022 Q4	$3.83M	Sell	599,853 -111,457	-16%	-$870K	﹤0.01%	2491
2022 Q3	$6.81M	Sell	711,310 -155,446	-18%	-$1.79M	﹤0.01%	2126
2022 Q2	$9.57M	Sell	866,756 -905,251	-51%	-$11.9M	﹤0.01%	1964
2022 Q1	$29.5M	Buy	1,772,007 +104,913	+6%	+$1.62M	0.01%	1431
2021 Q4	$31.8M	Sell	1,667,094 -51,839	-3%	-$1.14M	0.01%	1443
2021 Q3	$42.4M	Sell	1,718,933 -20,842	-1%	-$491K	0.01%	1245
2021 Q2	$45.3M	Buy	1,739,775 +231,203	+15%	+$6.01M	0.01%	1208
2021 Q1	$47.8M	Buy	1,508,572 +20,571	+1%	+$853K	0.01%	1139
2020 Q4	$69M	Buy	1,488,001 +417,070	+39%	+$16.6M	0.02%	842
2020 Q3	$35.3M	Buy	1,070,931 +20,388	+2%	+$625K	0.01%	1111
2020 Q2	$28.8M	Buy	1,050,543 +166,468	+19%	+$5.47M	0.01%	1202
2020 Q1	$26.5M	Buy	884,075 +314,369	+55%	+$8.33M	0.01%	1119
2019 Q4	$15.8M	Buy	569,706 +38,208	+7%	+$869K	﹤0.01%	1709
2019 Q3	$9.67M	Sell	531,498 -27,673	-5%	-$612K	﹤0.01%	1958
2019 Q2	$13.7M	Buy	559,171 +84,683	+18%	+$1.28M	﹤0.01%	1782
2019 Q1	$4.51M	Sell	474,488 -3,077	-0.6%	-$29.9K	﹤0.01%	2379
2018 Q4	$4.23M	Buy	477,565 +122,731	+35%	+$1.18M	﹤0.01%	2396
2018 Q3	$3.99M	Sell	354,834 -784	-0.2%	-$11.1K	﹤0.01%	2509
2018 Q2	$4.55M	Sell	355,618 -72,591	-17%	-$1.06M	﹤0.01%	2445
2018 Q1	$7.24M	Buy	428,209 +106,859	+33%	+$1.62M	﹤0.01%	2158
2017 Q4	$2.57M	Buy	321,350 +59,658	+23%	+$479K	﹤0.01%	2710
2017 Q3	$2.03M	Buy	261,692 +17,338	+7%	+$110K	﹤0.01%	2831
2017 Q2	$1.8M	Buy	244,354 +20,439	+9%	+$130K	﹤0.01%	2910
2017 Q1	$1.67M	Buy	223,915 +692	+0.3%	+$5.07K	﹤0.01%	2961
2016 Q4	$1.55M	Buy	223,223 +31,968	+17%	+$220K	﹤0.01%	3013
2016 Q3	$1.57M	Buy	191,255 +7,624	+4%	+$64.5K	﹤0.01%	2913
2016 Q2	$1.49M	Buy	183,631 +5,001	+3%	+$31.4K	﹤0.01%	2885
2016 Q1	$907K	Sell	178,630 -13,305	-7%	-$72.8K	﹤0.01%	3125
2015 Q4	$1.48M	Buy	191,935 +12,331	+7%	+$85.6K	﹤0.01%	2892
2015 Q3	$1.03M	Sell	179,604 -22,140	-11%	-$172K	﹤0.01%	3167
2015 Q2	$1.85M	Buy	+201,744	New	+$2.25M	﹤0.01%	2972

Other funds holding IOVA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JAM

Jupiter Asset Management London, United Kingdom $20.2B AUM 29.18% 1-Year Est. Return

RHJA

Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return

CWG

C WorldWide Group Copenhagen, Denmark $4.15B AUM 13.14% 1-Year Est. Return

MCP

Mirador Capital Partners Pleasanton, California $817M AUM 42.46% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

HWAM

Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return

Swiss National Bank Zurich, Switzerland $191B AUM 45.21% 1-Year Est. Return

Bank of New York Mellon's IOVA Position: Q2 2026 in Review

Bank of New York Mellon increased its Iovance Biotherapeutics (IOVA) stake by 21% in Q2 2026, buying an estimated $780K and bringing the position to 1,162,097 shares worth $4.83M. The position accounts for ﹤0.01% of the portfolio, ranked #2457.

Bank of New York Mellon first reported a position in IOVA in Q2 2015 and has held it in 45 quarters since. The position peaked at $69M in Q4 2020. 121 funds tracked by Wall St. Rank hold IOVA as of Q2 2026.

Bank of New York Mellon held 1,162,097 shares of Iovance Biotherapeutics worth $4.83M as of Q2 2026.
Bank of New York Mellon bought 205,317 Iovance Biotherapeutics shares in Q2 2026, an estimated $780K.
Iovance Biotherapeutics made up ﹤0.01% of Bank of New York Mellon's portfolio in Q2 2026, its #2457 holding.
Bank of New York Mellon first reported a position in Iovance Biotherapeutics in Q2 2015 and has held it in 45 quarters since.
Bank of New York Mellon's Iovance Biotherapeutics position peaked at $69M in Q4 2020.
121 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2026.

Based on Bank of New York Mellon's 13F filing for Q2 2026, filed 6 Aug 2026.